Cargando…

Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022

OBJECTIVES: We estimated the BNT162b2 vaccine effectiveness (VE) against any (symptomatic or not) SARS-CoV-2 Delta and Omicron infection among adolescents (aged 12-17 years) in Norway from August 2021 to January 2022. METHODS: We used Cox proportional hazard models, where vaccine status was included...

Descripción completa

Detalles Bibliográficos
Autores principales:	Veneti, Lamprini, Berild, Jacob Dag, Watle, Sara Viksmoen, Starrfelt, Jostein, Greve-Isdahl, Margrethe, Langlete, Petter, Bøås, Håkon, Bragstad, Karoline, Hungnes, Olav, Meijerink, Hinta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991321/ https://www.ncbi.nlm.nih.gov/pubmed/36893942 http://dx.doi.org/10.1016/j.ijid.2023.03.004

Ejemplares similares

Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021
por: Seppälä, Elina, et al.
Publicado: (2021)

Estimated vaccine effectiveness against SARS-CoV-2 Delta and Omicron infections among health care workers and the general adult population in Norway, August 2021 – January 2022
por: Langlete, Petter, et al.
Publicado: (2023)

Minimal transmission of SARS-CoV-2 from paediatric COVID-19 cases in primary schools, Norway, August to November 2020
por: Brandal, Lin T, et al.
Publicado: (2021)

Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July–November 2021
por: Starrfelt, Jostein, et al.
Publicado: (2022)

No difference in risk of hospitalization between reported cases of the SARS-CoV-2 Delta variant and Alpha variant in Norway
por: Veneti, Lamprini, et al.
Publicado: (2022)

Comprehensive Contact Tracing, Testing and Sequencing Show Limited Transmission of SARS-CoV-2 between Children in Schools in Norway, August 2020 to May 2021
por: Winje, Brita Askeland, et al.
Publicado: (2021)

Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022
por: Veneti, Lamprini, et al.
Publicado: (2022)

Increased risk of hospitalisation and intensive care admission associated with reported cases of SARS-CoV-2 variants B.1.1.7 and B.1.351 in Norway, December 2020 –May 2021
por: Veneti, Lamprini, et al.
Publicado: (2021)

Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021
por: Brandal, Lin T., et al.
Publicado: (2021)

High vaccine effectiveness against coronavirus disease 2019 (COVID-19) and severe disease among residents and staff of long-term care facilities in Norway, November 2020–June 2021
por: Starrfelt, Jostein, et al.
Publicado: (2022)

Trajectories of hospitalisation for patients infected with SARS-CoV-2 variant B.1.1.7 in Norway, December 2020 – April 2021
por: Whittaker, Robert, et al.
Publicado: (2021)

Molecular Epidemiology of the Norwegian SARS-CoV-2 Delta Lineage AY.63
por: Moen, Line Victoria, et al.
Publicado: (2022)

Poor neutralizing antibody responses against SARS‐CoV‐2 Omicron BQ.1.1 and XBB in Norway in October 2022
por: Vikse, Elisabeth Lea, et al.
Publicado: (2023)

Large outbreak of mumps virus genotype G among vaccinated students in Norway, 2015 to 2016
por: Veneti, Lamprini, et al.
Publicado: (2018)

Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study
por: Andersson, Niklas Worm, et al.
Publicado: (2023)

Community spread and late season increased incidence of oseltamivir‐resistant influenza A(H1N1) viruses in Norway 2016
por: Bragstad, Karoline, et al.
Publicado: (2019)

Abrupt termination of the 2019/20 influenza season following preventive measures against COVID-19 in Denmark, Norway and Sweden
por: Emborg, Hanne-Dorthe, et al.
Publicado: (2021)

Evaluation of the pilot wastewater surveillance for SARS-CoV-2 in Norway, June 2022 – March 2023
por: Amato, Ettore, et al.
Publicado: (2023)

Risk factors, immune response and whole‐genome sequencing of SARS‐CoV‐2 in a cruise ship outbreak in Norway
por: Gravningen, Kirsten, et al.
Publicado: (2022)

Cost-effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccine
por: Watle, Sara Viksmoen, et al.
Publicado: (2021)

Secondary attack rates of COVID-19 in Norwegian families: a nation-wide register-based study
por: Telle, Kjetil, et al.
Publicado: (2021)

Experience with open schools and preschools in periods of high community transmission of COVID-19 in Norway during the academic year of 2020/2021
por: Stebbings, Sara, et al.
Publicado: (2022)

High frequency of enterovirus D68 in children hospitalised with respiratory illness in Norway, autumn 2014
por: Bragstad, Karoline, et al.
Publicado: (2015)

Prevalence of antibodies against SARS‐CoV‐2 in the Norwegian population, August 2021
por: Tunheim, Gro, et al.
Publicado: (2022)

How many dinosaur species were there? Fossil bias and true richness estimated using a Poisson sampling model
por: Starrfelt, Jostein, et al.
Publicado: (2016)

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
por: Wisløff, Torbjørn, et al.
Publicado: (2018)

Short-term safety of COVID-19 mRNA vaccines with respect to all-cause mortality in the older population in Norway
por: Lopez-Doriga Ruiz, Paz, et al.
Publicado: (2023)

Healthcare use in 700 000 children and adolescents for six months after covid-19: before and after register based cohort study
por: Magnusson, Karin, et al.
Publicado: (2022)

Human to animal transmission of influenza A(H1N1)pdm09 in a turkey breeder flock in Norway
por: Sjurseth, Siri Kulberg, et al.
Publicado: (2017)

Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses
por: Andersson, Niklas Worm, et al.
Publicado: (2023)

Transmission of SARS-CoV-2 in Norwegian schools during academic year 2020-21: population wide, register based cohort study
por: Rotevatn, T A, et al.
Publicado: (2022)

Vesicles From Vibrio cholerae Contain AT-Rich DNA and Shorter mRNAs That Do Not Correlate With Their Protein Products
por: Langlete, Petter, et al.
Publicado: (2019)

Length of hospital stay and risk of intensive care admission and in-hospital death among COVID-19 patients in Norway: a register-based cohort study comparing patients fully vaccinated with an mRNA vaccine to unvaccinated patients
por: Whittaker, Robert, et al.
Publicado: (2022)

Analysis of Thromboembolic and Thrombocytopenic Events After the AZD1222, BNT162b2, and MRNA-1273 COVID-19 Vaccines in 3 Nordic Countries
por: Dag Berild, Jacob, et al.
Publicado: (2022)

Infection prevention guidelines and considerations for paediatric risk groups when reopening primary schools during COVID-19 pandemic, Norway, April 2020
por: Johansen, Tone Bjordal, et al.
Publicado: (2020)

Risk factors for SARS-CoV-2 infection and hospitalisation in children and adolescents in Norway: a nationwide population-based study
por: Størdal, Ketil, et al.
Publicado: (2022)

Limbic Encephalitis following Allogeneic Hematopoietic Stem Cell Transplantation
por: Johansen, Silje, et al.
Publicado: (2022)

Association of COVID-19 Vaccination During Pregnancy With Incidence of SARS-CoV-2 Infection in Infants
por: Carlsen, Ellen Øen, et al.
Publicado: (2022)

Modelling the burden of hepatitis C infection among people who inject drugs in Norway, 1973–2030
por: Meijerink, Hinta, et al.
Publicado: (2017)

Evolution of Bordetella pertussis in the acellular vaccine era in Norway, 1996 to 2019
por: Brandal, Lin T., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l53d6keve1npafq8k9cqbbbu1h